Rahul Banerjee: Dual-targeting CAR-T in Multiple Myeloma same week
Rahul Banerjee, Assistant Professor at UW Medicine, shared a posts on X:
“Research letter in JAMA Oncolgy – GC012F rapid-manufacturing BCMA/CD19 CAR-T in new Drugs Multiple Myeloma (n=22).
100% MRD-neg eventually, but unfortunately not reliably checked at D+28. Remains very promising – looking forward to data in larger dara-exposed cohort!”
B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma
Autors:
Source: Rahul Banerjee/X
“Another chinese dual-targeting CAR-T in Multiple Myeloma same week! Ph1 trial of BCMA/GPRC5D (e.g., “tec/tal” but CAR-T) in The Lancet Haematology.
BCMA assessed by flow, GPRC5D by IHC. n=21 infused, responses quite good! No Gr3+ skin changes, no (!) dysgeusia, no cerebellar tox.”
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
Autors: Dian Zhou, Qian Sun, Jieyun Xia, Weiying Gu, Jun Qian, Wanchuan Zhuang, Zhiling Yan, Hai Cheng, Wei Chen, Feng Zhu, Kunming Qi, Depeng Li, Wei Sang, Lili Zhu, Sha Ma, Hujun Li, Huanxin Zhang, Tingting Qiu, Dongmei Yan, Yanlei Zhang, Shuixiu Peng, Alex H Chang, Kailin Xu, Zhenyu Li,
